



Intravenous news: Medpage Today report “Hydroxyethyl starch solutions used to treat hypovolemia must carry a boxed warning about increased risk of kidney injury and death, the FDA said Monday. The move comes 2 weeks after an expert advisory committee in the European Union recommended that these products be pulled from the market entirely. Hydroxyethyl starch is a key component of infusion solutions used to expand blood volume in certain clinical situations, such as septic shock or open heart surgery with cardiopulmonary bypass.”

